Likelihood of Approval and Phase Transition Success Rate Model – Dostarlimab in Soft Tissue Sarcoma
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Dostarlimab in Soft Tissue Sarcoma report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Dostarlimab in Soft Tissue Sarcoma Drug Details:
Dostarlimab (Jemperli) is a immunoglobulin G4 humanized monoclonal antibody, acts as anti neoplastic agent. It is formulated as solution and concentrate solution for intravenous route of administration. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.Dostarlimab is under development for the treatment of solid tumors including high-grade neuroendocrine carcinoma, advanced small cell lung cancer, triple negative breast cancer, colorectal cancer, metastatic pancreatic ductal adenocarcinoma, recurrent and metastatic head and neck squamous cell carcinoma, laryngeal cancer, hypopharyngeal cancer, oropharyngeal cancer, oral cavity cancer squamous and non-squamous non-small cell lung carcinoma, malignant pleural mesothelioma, cervical cancer, rectal adenocarcinoma, acral melanoma, metastatic microsatellite instability high (MSI-H) endometrial cancer, epithelial ovarian cancer, peritoneal cancer, gestational trophoblastic neoplasia (GTN), fallopian tube cancer, adrenocortical carcinoma, neuroendocrine carcinoma, pancreatic adenocarcinoma, duodenum and small bowel adenocarcinoma, gastric and oeso-gastric junction (OGJ) adenocarcinoma, soft tissue sarcoma, ampulla of Vater adenocarcinoma, penile cancer, vaginal cancer, vulvar cancer who have progressed following one or two prior chemotherapy treatments and first line/second line non-small cell lung cancer and pan-deficient mismatch repair tumors (PdMMRT) (solid tumor), colon cancer. It is also under development for Hodgkin lymphoma, high grade glioma, low grade glioma, glioblastoma multiforme, diffuse intrinsic pontine glioma (DIPG), ependymoma, hepatic tumors including hepatoblastoma, hepatocellular carcinoma (HCC), fibrolamellar carcinoma and rhabdomyosarcoma. It is administered intravenously. It is an anti-PD-1 mAb. The drug candidate acts by targeting the PD-1 which has the potential to activate anti-tumor immunity. The drug candidate is developed based on somatic hypermutation (SHM) technology platform (SHM-XEL platform).It was under development for the treatment of metastatic clear cell sarcoma, refractory osteosarcoma, neuroblastoma, adrenocortical carcinoma, ewing sarcoma, rhabdomyosarcoma, metastatic urothelial bladder cancer, gastric cancer, adenocarcinoma of the gastroesophageal junction, head and neck cancer, biliary tract cancer, clear cell renal cell carcinoma.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Dostarlimab LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports